IDEAYA CFO granted option on 170,000 shares

IDEAYA Biosciences Chief Financial Officer receives new stock option grant.

Rhea-AI Filing Summary

IDEAYA Biosciences Chief Financial Officer receives new stock option grant. On January 30, 2026, CFO Joshua Bleharski was granted a stock option to purchase 170,000 shares of IDEAYA common stock at an exercise price of $32.19 per share, expiring on January 30, 2036.

According to the vesting terms, 25% of the option vests on the first anniversary of January 1, 2026, and the remaining shares vest in equal monthly installments over the following three years, so the option becomes fully vested on the fourth anniversary of the vesting commencement date.

Insider Trade Summary

Grant/Award: 170,000 shares

Grant/Award 1 txn

Insider Bleharski Joshua

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	170,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 170,000 contracts (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option was granted to IDEAYA (IDYA) CFO Joshua Bleharski?

IDEAYA’s CFO Joshua Bleharski was granted a stock option for 170,000 shares of common stock at an exercise price of $32.19 per share. This option gives him the right to buy shares at that price if and when the option is vested and exercised.

When was the IDEAYA (IDYA) CFO stock option grant made?

The stock option grant to IDEAYA’s CFO was made on January 30, 2026. This grant date is when the option terms were established, including the exercise price of $32.19 per share and the future vesting and expiration schedule for the 170,000 underlying shares.

How does the IDEAYA (IDYA) CFO stock option vest?

The option vests over four years from a January 1, 2026 vesting commencement date. 25% of the shares vest on the first anniversary, and the remaining shares vest in equal monthly installments, so the entire 170,000-share option is fully vested after four years.

What is the expiration date of the IDEAYA (IDYA) CFO stock option?

The CFO’s stock option expires on January 30, 2036. After that date, any unexercised portion of the option can no longer be used to purchase IDEAYA common stock at the $32.19 exercise price specified in the grant’s terms.

How many derivative securities does the IDEAYA (IDYA) CFO hold after this transaction?

Following this grant, the IDEAYA CFO beneficially owns 170,000 derivative securities related to this stock option, held with direct ownership. These derivative securities represent rights to acquire IDEAYA common stock if the option is exercised under its vesting and expiration terms.

Is the IDEAYA (IDYA) CFO stock option grant a purchase or an award?

The Form 4 shows the transaction code “A”, indicating an award or grant of a derivative security, not an open-market purchase. The CFO received an option covering 170,000 shares at a fixed exercise price of $32.19 per share, with no price paid for the option itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 08:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bleharski Joshua

(Last) (First) (Middle)

C/O IDEAYA BIOSCIENCES, INC.

5000 SHORELINE COURT, SUITE 300

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IDEAYA Biosciences, Inc. [ IDYA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$32.19	01/30/2026		A		170,000		(1)	01/30/2036	Common Stock	170,000	$0	170,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

	/s/ Joshua Bleharski	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.